SCHEDULE: Millennium Entities Disclose 8.5% Stake in Surrozen
Beneficial Ownership Report
Millennium Management and related entities have disclosed an 8.5% beneficial ownership stake in Surrozen, Inc. common stock as of December 31, 2025.
Summary
- Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed an Amendment No. 1 to Schedule 13G.
- The filing reports beneficial ownership of common stock, par value $0.0001 per share, of Surrozen, Inc. (CUSIP 86889P208).
- The event date requiring this filing was December 31, 2025.
- Integrated Core Strategies (US) LLC beneficially owns 718,724 shares, representing 8.4% of the class, with shared voting and dispositive power.
- Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each beneficially own 726,193 shares, representing 8.5% of the class, with shared voting and dispositive power.
- The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Surrozen, Inc.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive development, as the disclosure of a significant stake by a reputable institutional investor group like Millennium Management can instill confidence among other investors and potentially validate Surrozen's strategic direction or asset value.
Positives
- A significant institutional investor group, Millennium Management and its affiliates, has disclosed a substantial stake in Surrozen, Inc., which can be viewed as a vote of confidence in the company's prospects.
- The collective beneficial ownership of 8.5% by a prominent investment firm suggests a thorough due diligence process and belief in the long-term value of Surrozen, Inc.
Future Outlook
NA
Management Comments
- Gil Raviv, Global General Counsel for Integrated Core Strategies (US) LLC, Millennium Management LLC, and Millennium Group Management LLC, certified that the information set forth in the statement is true, complete, and correct.
- Israel A. Englander certified that the information set forth in the statement is true, complete, and correct.
- The reporting persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that the disclosure of a significant stake by a well-known hedge fund group like Millennium Management often attracts attention from other institutional investors and can signal a perceived undervaluation or strong growth potential within the biotechnology sector, where Surrozen, Inc. operates.
Stakeholder Impact
- Shareholders may view the significant institutional ownership as a positive indicator, potentially leading to increased investor confidence and interest in Surrozen, Inc.'s stock.
- The company's management may benefit from the implied validation of their strategy by a major institutional investor, though they must remain mindful of the interests of all shareholders.
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Date of event which requires the filing of this statement (beneficial ownership threshold met). |
| 02/04/2026 | Date of signing and filing of the Joint Filing Agreement and Schedule 13G Amendment No. 1. |
Recommendation
holdA 'hold' recommendation is appropriate because while the disclosure of a significant institutional stake by Millennium Management is a positive signal, a Schedule 13G filing primarily reports ownership and does not provide comprehensive financial or operational details to warrant a 'buy' or 'sell' recommendation. It indicates institutional interest and potential long-term value, suggesting investors monitor the stock for further developments rather than making immediate aggressive moves based solely on this ownership report.
Keywords
Surrozen Inc, Millennium Management, Integrated Core Strategies, Israel A. Englander, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.